Impact of curative surgery on bone in a patient with osteitis fibrosa cystica of primary hyperparathyroidism

Samantha Sathyakumar,1 Kripa Elizabeth Cherian,2 Sahana Shetty,3 Thomas Vizhalil Paul3

1Department of Endocrinology, Diabetes & Metabolism, Christian Medical College, Vellore, Tamil Nadu, India
2Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India
3Christian Medical College, Vellore, Tamil Nadu, India

Correspondence to Professor Thomas Vizhalil Paul, thomasvpaul@yahoo.com

Accepted 11 March 2016

DESCRIPTION

A 28-year-old woman presented with bone pains and progressive proximal muscle weakness of 2 years duration. Examination revealed significant bony tenderness over the spine and both hips and severe proximal muscle weakness in the lower limbs. The rest of the examination was normal. Biochemical evaluation showed parathyroid hormone (PTH)-dependent hypercalcaemia (serum calcium 12.4 mg/dL (normal 8.4–10.2); PTH >1900 pg/mL (normal 8–50)). Remaining blood bone biochemistry was as follows: phosphorus 2 mg/dL (normal 2.5–4.5), alkaline phosphatase 1112 U/L (normal 40–125), creatinine 0.9 mg/dL (normal 0.6–1.2) and 25 hydroxy vitamin D 12.5 ng/mL (normal 30–75). A skeletal survey performed was diagnostic of osteitis fibrosa cystica with multiple cystic lesions secondary to brown tumours in the pelvis and femoral bones (figure 1A). A marked reduction in bone mineral density (BMD) was seen at all sites (figure 2). There was no evidence of renal stones. A technetium-sestamibi uptake scan revealed a lesion in the left superior parathyroid (figure 3). Thus the patient was diagnosed as having severe parathyroid hyperfunctioning adenoma and vitamin D deficiency. She was treated with hydration and cholecalciferol. She underwent a focused parathyroidectomy following which her calcium normalised and histopathology was consistent with a parathyroid adenoma. She was continued on vitamin D supplementation. She made a remarkable improvement after surgery and was asymptomatic with neither bone pain nor muscle weakness at the end of 1 year. Her serum calcium was 8.6 mg/dL. There was normalisation of BMD at two sites and remineralisation of lytic lesions in the pelvis and femur (figures 1B, C and 2).

Skeletal lesions associated with hyperparathyroidism account for a large part of the morbidity associated with this condition. However, with the advent of routine screening for calcium levels, advanced disease has become uncommon in the Western population. On the contrary, overt manifestations of hyperparathyroidism including osteitis fibrosa cystica, renal stones and pancreatitis, continue to be seen in developing countries such as India. Brown tumours seen in osteitis fibrosa cystica commonly affect the tibia, femur, pelvis, vertebrae, ribs and mandible. After successful parathyroidectomy, recovery of bone mass occurs earlier at sites with cancellous bone as compared with those of cortical bone.2

Figure 1 Serial X-rays of the pelvis showing improvement following parathyroidectomy in osteitis fibrosa cystica.
Figure 2  Bone mineral density (BMD) before and 6 months and 1 year following parathyroidectomy.

Figure 3  Sestamibi scan showing left superior parathyroid adenoma.
Learning points

▸ Overt manifestations of primary hyperparathyroidism including osteitis fibrosa cystica, renal stones and pancreatitis continue to be seen in developing countries such as India.
▸ Severity of the bone disease in primary hyperparathyroidism is further aggravated by coexisting vitamin D deficiency.
▸ Brown tumours seen in osteitis fibrosa cystica commonly affect the tibia, femur, pelvis, vertebrae, ribs and mandible and parathyroidectomy is the definitive treatment of hypercalcaemia secondary to primary hyperparathyroidism and can dramatically improve osteitis fibrosa cystica.

Acknowledgements
The authors thank Dr Deepak Abraham for surgical management; Dr Julie Hepzibah for the Nuclear Medicine imaging; Ms Banu Shankar for secretarial help.

Contributors
SS, KEC and SS wrote the manuscript. SS, KEC, SS and TVP reviewed and approved the manuscript.

Competing interests
None declared.

Patient consent
Obtained.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES